This article is more than 5 years old. Information may no longer be current.
CCFA partners with Pfizer to support novel IBD research
The Crohn’s & Colitis Foundation of America has partnered with Pfizer’s Centers for Therapeutic Innovation to support new research in inflammatory bowel disease, according to a CCFA press release.
The organizations will work together toward the goal of helping translational IBD research projects reach the clinical setting.
Caren Heller
“We are pleased to have this opportunity to collaborate with CTI to help identify and advance potential new treatments and therapies for people with IBD,” Caren Heller, MD, MBA, and CCFA’s chief scientific officer, said in the press release. “We aim to speed the development of better treatments for millions of patients with IBD.”
In the CCFA’s first joint-funding agreement with a pharmaceutical company, the organizations will initiate their partnership by co-funding research that focuses on validated targets in Crohn’s disease and ulcerative colitis. During the next 2 years they will finance up to four small-molecule projects, the release said.
“CTI’s work is based on authentic collaboration, reflected in shared decision making and aligned incentives, in an effort to bring together some of the world’s best resources to develop medicines faster,” Anthony J. Coyle, PhD, and Pfizer CTI’s chief scientific officer, said in the release. “Combining CTI’s scientific resources with CCFA’s deep knowledge of IBD and network of investigators, we aim to be well-positioned to pursue more targeted medicines for IBD patients.”